少腹逐瘀颗粒联合屈螺酮炔雌醇治疗子宫内膜异位症的临床研究

目的探讨采用少腹逐瘀颗粒联合屈螺酮炔雌醇治疗子宫内膜异位症的临床疗效。方法选取中山医院青浦分院2015年3月—2016年3月收治的子宫内膜异位症患者121例,随机分成对照组(60例)和治疗组(61例)。对照组患者口服屈螺酮炔雌醇片,1片/次,1次/d,月经来潮后第5天服用,连续使用至下次月经来潮为1个周期;治疗组患者在对照组基础上口服少腹逐瘀颗粒,0.6 g/次,2次/d。两组患者连续治疗3个月经周期。评价两组患者临床疗效,同时比较治疗前后两组患者CA125水平、痛经评分、盆腔包块体积、痛觉、生育能力、复发率和不良反应。结果治疗后,对照组的临床总有效率为81.67%,显著低于治疗组患者的96.72%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者CA125水平、痛经评分和盆腔包块直径均明显降低(P0.05);且治疗后治疗组患者的CA125水平、痛经评分和盆腔包块直径比对照组降低的更明显(P0.05)。随访1年发现,治疗组患者复发率明显低于对照组(P0.05),且治疗组生育能力明显强于对照组(P0.05),痛觉人数明显少于对照组(P0.05)。治疗期间,对照组患者的不良反应发生率为21.67%,明显高于治疗组患者的6.56%,两组比较差异具有统计学意义(P0.05)。结论少腹逐瘀颗粒联合屈螺酮炔雌醇治疗子宫内膜异位症疗效显著,安全性高,具有一定的临床推广应用价值。

Clinical study on Shaofu Zhuyu Granules combined with drospirenone and ethinylestradiol in treatment of endometriosis

Objective To explore the clinical efficacy of Shaofu Zhuyu Granules combined with drospirenone and ethinylestradiol in treatment of endometriosis. Methods Patients (121 cases) with endometriosis in Qingpu Branch of Zhongshan Hospital from March 2015 to March 2016 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Drospirenone and Ethinylestradiol Tablets after the fifth days of menstruation until the next menstruation, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shaofu Zhuyu Granules on the basis of the control group, 0.6 g/time, twice daily. Patients in two groups were treated for three menstrual periods. After treatment, the clinical efficacy was evaluated, and the CA125 levels, dysmenorrhea scores, and pelvic mass volume, pain, potentia generandi, recurrence rates, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.67%, which was significantly lower than 96.72% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the CA125 level, dysmenorrhea scores, and pelvic mass volume were significantly decreased (P<0.05). And these indicators in the treatment group decreased more significantly than those in the control group (P<0.05). Follow up for 1 year showed that recurrence rate in the treatment group was significantly lower than that in the control group (P<0.05), and the potentia generandi of the treatment group was significantly stronger than that of the control group (P<0.05), the patients of pain were significantly less than those in the control group (P<0.05). During the treatment, the adverse reaction rate in the control group was 21.67%, which was significantly higher than 6.56% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Shaofu Zhuyu Granules combined with drospirenone and ethinylestradiol has a significant effect in treatment of endometriosis with high safety, which has a certain clinical application value.